Neuburgh Advisers’s Alder Biopharmaceuticals ALDR Stock Holding History

Neuburgh Advisers’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-25,568	Closed	-$426K	–	947
2018 Q3	$426K	Buy	25,568 +15,062	+143%	+$272K	0.01%	507
2018 Q2	$166K	Buy	10,506 +986	+10%	+$15K	0.01%	696
2018 Q1	$121K	Buy	+9,520	New	+$138K	﹤0.01%	755

Other funds holding ALDR

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Neuburgh Advisers's ALDR Position: Q4 2018 in Review

Neuburgh Advisers sold out of Alder Biopharmaceuticals (ALDR) in Q4 2018, closing a stake of 25,568 shares — an estimated $426K sold.

Neuburgh Advisers first reported a position in ALDR in Q1 2018 and held it in 3 quarters. The position peaked at $426K in Q3 2018. 124 funds tracked by Wall St. Rank hold ALDR as of Q4 2018.

Neuburgh Advisers reported no remaining Alder Biopharmaceuticals position as of Q4 2018 after selling out during the quarter.
Neuburgh Advisers sold 25,568 Alder Biopharmaceuticals shares in Q4 2018, an estimated $426K.
Neuburgh Advisers first reported a position in Alder Biopharmaceuticals in Q1 2018 and held it in 3 quarters.
Neuburgh Advisers's Alder Biopharmaceuticals position peaked at $426K in Q3 2018.
124 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2018.

Based on Neuburgh Advisers's 13F filing for Q4 2018, filed 13 Feb 2019.